SCHEMBL2498883

SCHEMBL2498883

COc1ccccc1C1(N2CC(F)C[C@H]2C(=O)N2CCC2)C(=O)Nc2ccc(Cl)cc21

nearest known ligand 0.40

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ACHE P22303 9/20 0.40
AVPR2 P30518 1/20 0.39
OXTR P30559 1/20 0.39
AVPR1A P37288 1/20 0.39
AVPR1B P47901 1/20 0.39
GPR65 Q8IYL9 1/20 0.39
KDM4E B2RXH2 1/20 0.38
PKM P14618 1/20 0.38
TSHR P16473 1/20 0.38
MMP13 P45452 1/20 0.36
ADAM17 P78536 1/20 0.36
ADAMTS5 Q9UNA0 1/20 0.36
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5355921 0.91 AVPR1A (0.48) ACHEAVPR2OXTRAVPR1AAVPR1B
SCHEMBL5065998 0.89 ACHE (0.42) ACHEAVPR2OXTRAVPR1AAVPR1B
SCHEMBL2493765 0.88 BRD4 (0.44) ACHEAVPR2OXTRAVPR1AAVPR1B
SCHEMBL2499338 0.87 AVPR1A (0.52) ACHEAVPR2OXTRAVPR1AAVPR1B
SCHEMBL4479387 0.87 AVPR1A (0.52) ACHEAVPR2OXTRAVPR1AAVPR1B
SCHEMBL2499389 0.87 AVPR1A (0.52) ACHEAVPR2OXTRAVPR1AAVPR1B
SCHEMBL2500497 0.87 AVPR1A (0.52) ACHEAVPR2OXTRAVPR1AAVPR1B
SCHEMBL2495369 0.85 AVPR2 (0.41) ACHEAVPR2OXTRAVPR1AAVPR1B
SCHEMBL2494967 0.85 AVPR2 (0.39) ACHEAVPR2OXTRAVPR1AAVPR1B
SCHEMBL2495725 0.81 BRD4 (0.40) ACHEAVPR2OXTRAVPR1AAVPR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8030499-B2 1,3-dihydro-2H-indole-2-one compound and pyrrolidine-2-one compound fused with aromatic heterocycle TAISHO PHARMACEUTICAL CO., LTD. (JP) 2011-10-04 US disclosed
US-7528124-B2 1,3-dihydro-2H-indol-2-one derivative TAISHO PHARMACEUTICAL CO., LTD. (JP) 2009-05-05 US disclosed
US-20080318923-A1 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle TAISHO PHARMACEUTICAL CO., LTD. (JP) 2008-12-25 US disclosed
US-20060276449-A1 1,3-Dihydro-2h-indol-2-one derivative TAISHO PHARMACEUTICAL CO., LTD. (JP) 2006-12-07 US disclosed
EP-1659121-A1 1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD (JP) 2006-05-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276449-A1 1,3-Dihydro-2h-indol-2-one derivative AVPR1B, AVPR2, AVPR1A ACHE 3126/4885AVPR2 2/4885OXTR 26/4885
US-20080318923-A1 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle AVPR1B, AVPR1A, AVPR2 ACHE 2436/4885AVPR2 3/4885OXTR 37/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.